HLS Therapeutics Inc Market Cap ($102.03 Million)
Market Cap & Net Worth: HLS Therapeutics Inc (HLS)
HLS Therapeutics Inc market cap. HLS Therapeutics Inc (TO:HLS) has a market capitalization of $102.03 Million (CA$141.04 Million) as of November 1, 2026. Listed on the TO stock exchange, this Canada-based company holds position #18935 globally and #619 in its home market, demonstrating a 8.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HLS Therapeutics Inc's stock price CA$4.51 by its total outstanding shares 31273681 (31.27 Million). Also see HLS operating cash flow for how efficiently the company converts equity into cash flow.
HLS Therapeutics Inc Market Cap History (2015–2026)
HLS Therapeutics Inc market cap history from 2015 to 2026. Data shows growth from $52.82 Million to $102.03 Million (6.03% CAGR). Check HLS live share price for real-time trading data and today's change.
HLS Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HLS Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore HLS Therapeutics Inc (HLS) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.93x
HLS Therapeutics Inc's market cap is 1.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $51.13 Million | $54.03 Million | -$874.93K | 0.95x | N/A |
| 2017 | $50.71 Million | $75.08 Million | -$6.10 Million | 0.68x | N/A |
| 2018 | $310.56 Million | $61.41 Million | -$24.81 Million | 5.06x | N/A |
| 2019 | $547.50 Million | $54.16 Million | -$19.55 Million | 10.11x | N/A |
| 2020 | $390.82 Million | $56.11 Million | -$15.33 Million | 6.97x | N/A |
| 2021 | $332.62 Million | $60.01 Million | -$13.12 Million | 5.54x | N/A |
| 2022 | $219.31 Million | $61.47 Million | -$23.60 Million | 3.57x | N/A |
| 2023 | $89.36 Million | $63.07 Million | -$27.53 Million | 1.42x | N/A |
| 2024 | $88.91 Million | $56.62 Million | -$19.66 Million | 1.57x | N/A |
| 2025 | $109.04 Million | $56.47 Million | -$12.65 Million | 1.93x | N/A |
Competitor Companies of HLS by Market Capitalization
Companies near HLS Therapeutics Inc in the global market cap rankings as of November 1, 2026. Also see HLS Therapeutics Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to HLS Therapeutics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of HLS Therapeutics Inc (2015–2026)
Market capitalization of HLS Therapeutics Inc from 2015 to today. Between 2015 and today, HLS Therapeutics Inc's market cap moved from $52.82 Million to $ 102.03 Million, with a yearly change of 6.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$102.03 Million | -6.43% |
| 2025 | CA$109.04 Million | +22.65% |
| 2024 | CA$88.91 Million | -0.51% |
| 2023 | CA$89.36 Million | -59.25% |
| 2022 | CA$219.31 Million | -34.06% |
| 2021 | CA$332.62 Million | -14.89% |
| 2020 | CA$390.82 Million | -28.62% |
| 2019 | CA$547.50 Million | +76.29% |
| 2018 | CA$310.56 Million | +512.41% |
| 2017 | CA$50.71 Million | -0.83% |
| 2016 | CA$51.13 Million | -3.20% |
| 2015 | CA$52.82 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of HLS Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $102.03 Million USD |
| MoneyControl | $102.03 Million USD |
| MarketWatch | $102.03 Million USD |
| marketcap.company | $102.03 Million USD |
| Reuters | $102.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more